140 related articles for article (PubMed ID: 37318485)
1. Intravenous N-acetylcysteine in respiratory disease with abnormal mucus secretion.
Tang W; Zhu D; Wu F; Xu JF; Yang JP; Deng ZP; Chen XB; Papi A; Qu JM
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(11):5119-5127. PubMed ID: 37318485
[TBL] [Abstract][Full Text] [Related]
2. A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis.
Ratjen F; Wönne R; Posselt HG; Stöver B; Hofmann D; Bender SW
Eur J Pediatr; 1985 Nov; 144(4):374-8. PubMed ID: 3908111
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of myrtol standardized in acute bronchitis. A multi-centre, randomised, double-blind, placebo-controlled parallel group clinical trial vs. cefuroxime and ambroxol.
Matthys H; de Mey C; Carls C; Ryś A; Geib A; Wittig T
Arzneimittelforschung; 2000 Aug; 50(8):700-11. PubMed ID: 10994153
[TBL] [Abstract][Full Text] [Related]
4. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease.
Poole P; Sathananthan K; Fortescue R
Cochrane Database Syst Rev; 2019 May; 5(5):CD001287. PubMed ID: 31107966
[TBL] [Abstract][Full Text] [Related]
5. [The application of n-acetylcysteine as an antioxidant and mucolytic in mechanical ventilation in intensive care patients. A prospective, randomized, placebo-controlled, double-blind study].
Konrad F; Schoenberg MH; Wiedmann H; Kilian J; Georgieff M
Anaesthesist; 1995 Sep; 44(9):651-8. PubMed ID: 7485927
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of ambroxol hydrochloride lozenges in sore throat. Randomised, double-blind, placebo-controlled trials regarding the local anaesthetic properties.
Fischer J; Pschorn U; Vix JM; Peil H; Aicher B; Müller A; de Mey C
Arzneimittelforschung; 2002; 52(4):256-63. PubMed ID: 12040968
[TBL] [Abstract][Full Text] [Related]
7. Improvement of mucociliary transport in smokers by mucolytics.
Olivieri D; Marsico SA; Del Donno M
Eur J Respir Dis Suppl; 1985; 139():142-5. PubMed ID: 3862608
[TBL] [Abstract][Full Text] [Related]
8. N-acetylcysteine in patients with COPD exacerbations associated with increased sputum.
Ayfer Aytemur Z; Baysak A; Ozdemir O; Köse T; Sayiner A
Wien Klin Wochenschr; 2015 Apr; 127(7-8):256-61. PubMed ID: 25595117
[TBL] [Abstract][Full Text] [Related]
9. Treatment with N-acetylcysteine during acute respiratory distress syndrome: a randomized, double-blind, placebo-controlled clinical study.
Domenighetti G; Suter PM; Schaller MD; Ritz R; Perret C
J Crit Care; 1997 Dec; 12(4):177-82. PubMed ID: 9459113
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of letosteine in the treatment of sputum thickening and expectoration difficulty in patients with respiratory diseases: a multicenter, randomized, double-masked, double dummy, positive drug parallel controlled trial.
Zhou Y; Sun S; Liu H; Cui L; Chang X; Sun Z
Pharmazie; 2014 Nov; 69(11):842-9. PubMed ID: 25985582
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Clinical Effectiveness Between Ambroxol and N-Acetylcysteine in Surgical Patients: A Retrospective Cohort Study.
Bian J; Liang H; Zhang M
J Clin Pharmacol; 2023 Feb; 63(2):172-179. PubMed ID: 36263951
[TBL] [Abstract][Full Text] [Related]
12. A controlled trial of ambroxol in chronic bronchitis.
Guyatt GH; Townsend M; Kazim F; Newhouse MT
Chest; 1987 Oct; 92(4):618-20. PubMed ID: 3308343
[TBL] [Abstract][Full Text] [Related]
13. [Mucolytics in acute and chronic respiratory tract disorders. I. Pathophysiology and mechanisms of action].
Kupczyk M; Kuna P
Pol Merkur Lekarski; 2002 Mar; 12(69):245-7. PubMed ID: 12053600
[TBL] [Abstract][Full Text] [Related]
14. The effect of N-acetylcysteine in patients with non-cystic fibrosis bronchiectasis (NINCFB): study protocol for a multicentre, double-blind, randomised, placebo-controlled trial.
Liao Y; Wu Y; Zi K; Shen Y; Wang T; Qin J; Chen L; Chen M; Liu L; Li W; Zhou H; Xiong S; Wen F; Chen J
BMC Pulm Med; 2022 Nov; 22(1):401. PubMed ID: 36344940
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of safety and efficacy of inhaled ambroxol in hospitalized adult patients with mucopurulent sputum and expectoration difficulty.
Zheng Z; Yang K; Liu N; Fu X; He H; Chen H; Xu P; Wang J; Liu M; Tang Y; Zhao F; Xu S; Yu X; Han J; Yuan B; Jia B; Pang G; Shi Y; Kuang M; Shao H; Xiong H; He J; Pan Y; Chen R
Front Med (Lausanne); 2023; 10():1182602. PubMed ID: 37305123
[TBL] [Abstract][Full Text] [Related]
16. Local anaesthetic properties of ambroxol hydrochloride lozenges in view of sore throat. Clinical proof of concept.
Schutz A; Gund HJ; Pschorn U; Aicher B; Peil H; Müller A; de Mey C; Gillissen A
Arzneimittelforschung; 2002; 52(3):194-9. PubMed ID: 11963647
[TBL] [Abstract][Full Text] [Related]
17. [Multicenter, double-blind study of oral acetylcysteine vs. placebo].
Brocard H; Charpin J; Germouty J
Eur J Respir Dis Suppl; 1980; 111():65-9. PubMed ID: 7011834
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of high dose N- Acetylcysteine on airway inflammation and quality of life outcomes in adults with bronchiectasis: A randomised placebo-controlled pilot study.
Jayaram L; King PT; Hunt J; Lim M; Park C; Hu E; Dousha L; Ha P; Bartlett JB; Southcott AM; Muruganandan S; Vogrin S; Rees MA; Dean OM; Wong CA
Pulm Pharmacol Ther; 2024 Mar; 84():102283. PubMed ID: 38141851
[TBL] [Abstract][Full Text] [Related]
19. Ambroxol in the 21st century: pharmacological and clinical update.
Malerba M; Ragnoli B
Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1119-29. PubMed ID: 18680446
[TBL] [Abstract][Full Text] [Related]
20. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial).
Malerba M; Ponticiello A; Radaeli A; Bensi G; Grassi V
Pulm Pharmacol Ther; 2004; 17(1):27-34. PubMed ID: 14643168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
